These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11339427)

  • 21. Metabolism of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 by blood derived macrophages from a patient with alveolar rhabdomyosarcoma during short-term culture and 1 alpha,25-dihydroxyvitamin D3 after long-term culture.
    Hayes ME; Bayley D; Drayson M; Freemont AJ; Denton J; Davies M; Mawer EB
    J Steroid Biochem Mol Biol; 1991 Mar; 38(3):301-6. PubMed ID: 2009222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
    Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.
    Pakkala S; de Vos S; Elstner E; Rude RK; Uskokovic M; Binderup L; Koeffler HP
    Leuk Res; 1995 Jan; 19(1):65-72. PubMed ID: 7837819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis.
    Jones CL; Vieth R; Spino M; Ledermann S; Kooh SW; Balfe J; Balfe JW
    Clin Nephrol; 1994 Jul; 42(1):44-9. PubMed ID: 7923966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 metabolism in calcium-deficient rats.
    Matsumoto T; Ikeda K; Yamato H; Morita K; Ezawa I; Fukushima M; Nishii Y; Ogata E
    Biochem J; 1988 Mar; 250(3):671-7. PubMed ID: 2839142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a sustained release formulation of 1,25-dihydroxyvitamin D3-glycosides for milk fever prevention on serum 1,25-dihydroxyvitamin D3, calcium and phosphorus in dairy cows.
    Bachmann H; Lanz M; Kehrle S; Bittner W; Toggenburger A; Mathis GA; Rambeck W
    J Steroid Biochem Mol Biol; 2017 Oct; 173():301-307. PubMed ID: 28342973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of 1,24(R)-dihydroxyvitamin D3-like bone-resorbing lipid in a patient with cancer-associated hypercalcemia.
    Shigeno C; Yamamoto I; Dokoh S; Hino M; Aoki J; Yamada K; Morita R; Kameyama M; Torizuka K
    J Clin Endocrinol Metab; 1985 Oct; 61(4):761-8. PubMed ID: 2993347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats.
    Jablonski G; Mortensen BM; Klem KH; Mosekilde L; Danielsen CC; Gordeladze JO
    Calcif Tissue Int; 1995 Nov; 57(5):385-91. PubMed ID: 8564802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone-forming ability of 24R,25-dihydroxyvitamin D3 in the hypophosphatemic mouse.
    Yamate T; Tanaka H; Nagai Y; Yamato H; Taniguchi N; Nakamura T; Seino Y
    J Bone Miner Res; 1994 Dec; 9(12):1967-74. PubMed ID: 7872063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
    Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
    Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.
    Yamato H; Matsumoto T; Fukumoto S; Ikeda K; Ishizuka S; Ogata E
    Endocrinology; 1989 Jan; 124(1):511-7. PubMed ID: 2783309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.
    Eisman JA; Barkla DH; Tutton PJ
    Cancer Res; 1987 Jan; 47(1):21-5. PubMed ID: 3024816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25-Dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats.
    Burnatowska-Hledin MA; Doyle TM; Eadie MJ; Mayor GH
    J Lab Clin Med; 1986 Aug; 108(2):96-102. PubMed ID: 3755457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
    Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study.
    Prytuła A; Walle JV; Van Vlierberghe H; Kaufman JM; Fiers T; Dehoorne J; Raes A
    Endocrine; 2016 Apr; 52(1):93-102. PubMed ID: 26433738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice.
    Abe J; Takita Y; Nakano T; Miyaura C; Suda T; Nishii Y
    Endocrinology; 1989 May; 124(5):2645-7. PubMed ID: 2539984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.
    Sung V; Feldman D
    Mol Cell Endocrinol; 2000 Jun; 164(1-2):133-43. PubMed ID: 11026565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3.
    Harada M; Miyahara T; Miyata M; Komiyama H; Sugure A; Ikemoto Y; Kondo S; Takamura T; Higuchi S; Otomo S
    Calcif Tissue Int; 1993 Nov; 53(5):318-23. PubMed ID: 8287319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.